🟢 Generate Biomedicines is trading 4.3% up today after Morgan Stanley conference highlighted AI-driven pipeline

Generate Biomedicines is trading 4.26% up at $16.39 after management presented at the Morgan Stanley Global Healthcare Conference on September 14, 2026.

• Executives emphasized the expanding AI-driven pipeline, including GB-0895’s Phase III asthma program.
• Management highlighted funding into early 2028.
• The gain contrasts with modestly weaker major indexes, suggesting company-specific investor interest rather than broad market momentum.